| Identification | Back Directory | [Name]
CCG21397 | [CAS]
433311-07-0 | [Synonyms]
MI-1
CCG21397
4-[4-(4,5-Dihydro-5,5-dimethyl-2-thiazolyl)-1-piperazinyl]-5,6,7,8-tetrahydro-[1]benzothieno[2,3-d]pyrimidine
[1]Benzothieno[2,3-d]pyrimidine, 4-[4-(4,5-dihydro-5,5-dimethyl-2-thiazolyl)-1-piperazinyl]-5,6,7,8-tetrahydro- | [Molecular Formula]
C19H25N5S2 | [MDL Number]
MFCD03268791 | [MOL File]
433311-07-0.mol | [Molecular Weight]
387.57 |
| Chemical Properties | Back Directory | [Boiling point ]
575.3±60.0 °C(Predicted) | [density ]
1.46±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble15mg/mL (clear solution, warmed) | [form ]
powder | [pka]
9.59±0.40(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
MI-1 inhibits Menin-MLL interaction with an IC50 of 1.9 μM[1]. | [References]
[1] Vedadi M, et al. Targeting human SET1/MLL family of proteins. Protein Sci. 2017 Apr;26(4):662-676. doi: 10.1002/pro.3129. Epub 2017 Mar 6. DOI:10.1002/pro.3129 |
|
| Company Name: |
PHARMEKS Ltd.
|
| Tel: |
+7 (495) 702-9648 |
| Website: |
www.pharmeks.com |
|